Open Access
Feature Article

Treating acne. How to minimise physical and emotional scarring

Open Access
Feature Article

Treating acne. How to minimise physical and emotional scarring

Jo-Ann See, PHILIP TONG

Figures

© WUTTICHOK/STOCK.ADOBE.COM
© WUTTICHOK/STOCK.ADOBE.COM
Dr See is a Dermatologist in private practice at Central Sydney Dermatology, Sydney; and is Co-Chair of the All About Acne group.
 Dr Tong is a Dermatologist in private practice at Central Sydney Dermatology and Visiting Medical Officer at St Vincent’s Hospital, Sydney, NSW. He is a member of the All About Acne group (www.acne.org.au).

 

Advertisement

References

1. See J-A, Zureigat M. A GP's guide to treating acne. Med Today 2015; 16(10): 34-40.
2. Bhate K, Williams HC. Epidemiology of acne vulgaris. Br J Dermatol 2013; 168: 474-485. 
3. Brown H, Tapley A, van Driel ML, et al. Acne in primary care: a cross-sectional analysis. Aust J Gen Pract 2019; 48: 781-788.
4. Goldberg JL, Dabade TS, Davis SA, Feldman SR, Krowchuk DP, Fleischer AB. Changing age of acne vulgaris visits: another sign of earlier puberty? Pediatr Dermatol 2011; 28: 645-648.
5. Gollnick HPM, Finlay AY, Shear N; Global Alliance to Improve Outcomes in Acne. Can we define acne as a chronic disease? If so, how and when? Am J Clin Dermatol 2008; 9: 279-284. 
6. Zouboulis CC. Acne as a chronic systemic disease. Clin Dermatol 2014; 32: 389-396.
7. Dunn LK, O’Neill JL, Feldman SR. Acne in adolescents: quality of life, self-esteem, mood, and psychological disorders. Dermatol Online J 2011; 17: 1. 
8. Gieler U, Gieler T, Kupfer JP. Acne and quality of life – impact and management. J Eur Acad Dermatol Venereol 2015; 29 Suppl 4: S12-S14.
9. Chernyshov PV, Zouboulis CC, Tomas-Aragones L, et al. Quality of life measurement in acne. Position paper of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa. J Eur Acad Dermatol Venereol 2018; 32: 194-208. 
10. Hay RJ, Johns NE, Williams HC, et al. The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions. J Invest Dermatol 2014; 134: 1527-1534. 
11. Karimkhani C, Dellavalle RP, Coffeng LE, et al. Global Skin Disease Morbidity and Mortality. An update from the Global Burden of Disease Study 2013. JAMA Dermatol 2017; 153: 406-412.
12. Tan J, Frey MP, Thiboutot D, Layton A, Eady A. Identifying the impacts of acne: a Delphi survey of patients and clinicians. J Cutan Med Surg 2020; 24: 259-266. 
13. Samuels DV, Rosenthal R, Lin R, Chaudhari S, Natsuaki MN. Acne vulgaris and risk of depression and anxiety: a meta-analytic review. J Am Acad Dermatol 2020; 83: 532-541. 
14. Yousaf A, Hagen R, Delaney E, Davis S, Zinn Z. The influence of social media on acne treatment. Pediatr Dermatol 2020; 37: 301-304.
15. Layton AM. Optimal management of acne to prevent scarring and psychological sequelae. Am J Clin Dermatol 2001; 2: 135-141. 
16. Britt H, Miller GC, Henderson J et al. General practice activity in Australia 2015-2016. General practice series number 40. Sydney, NSW: Sydney University Press; 2016. 
17. Baldwin H, Tan J. Effects of diet on acne and its response to treatment. Am J Clin Dermatol 2020; Aug 3. doi: 10.1007/s40257-020-00542-y.
18. Lee YH, Scharnitz TP, Muscat J, Chen A, Gupta-Elera G, Kirby JS. Laboratory monitoring during isotretinoin therapy for acne: a systematic review and meta-analysis. JAMA Dermatol 2016; 152: 35-44.
19. Kim JE, Park AY, Lee SY, Park YL, Whang KU, Kim H-J. Comparison of the efficacy of azithromycin versus doxycycline in acne vulgaris: a meta-analysis of randomized controlled trials. Ann Dermatol 2018; 30: 417-426.
20. Kardeh S, Saki N, Jowkar F, Kardeh B, Moein SA, Khorraminejad-Shirazi MH. Efficacy of azithromycin in treatment of acne vulgaris: a mini review. World J Plast Surg 2019; 8: 127-134.
21. Lowenstein EJ. Diagnosis and management of the dermatologic manifestations of the polycystic ovary syndrome. Dermatol Ther 2006; 19: 210-223.
22. Arowojolu AO, Gallo MF, Lopez LM, Grimes DA. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev 2012; (7): CD004425.
23. Kamangar F, Shinkai K. Acne in the adult female patient: a practical approach. Int J Dermatol 2012; 51: 1162-1174.
24. Brache V, Faundes A, Alvarez F, Cochon L. Nonmenstrual adverse events during use of implantable contraceptives for women: data from clinical trials. Contraception 2002; 65: 63-74.
25. Plovanich M, Weng QY, Mostaghimi A. Low usefulness of potassium monitoring among healthy young women taking spironolactone for acne. JAMA Dermatol 2015; 151: 941-944.
26. Rademaker M. Making sense of the effects of the cumulative dose of isotretinoin in acne vulgaris. Int J Dermatol 2016; 55: 518-523.
27. Magin P, Smith W. Isotretinoin, depression and suicide: a review of the evidence. Br J Gen Pract 2005; 55: 134-138.
28. Tan AU, Schlosser BJ, Paller AS. A review of diagnosis and treatment of acne in adult female patients. Int J Womens Dermatol 2018; 4: 56-71.
29. Jones TM, Ellman H, deVries T. Pharmacokinetic comparison of once-daily topical minocycline foam 4% versus oral minocycline for moderate to severe acne. J Drugs Dermatol 2017; 16: 1022-1028.
30. Mazzetti A, Moro L, Gerloni M, Cartwright M. Pharmacokinetic profile, safety, and tolerability of clascoterone (cortexolone 17-alpha propionate, CB-03-01) topical cream, 1% in subjects with acne vulgaris: an open-label phase 2a study. J Drugs Dermatol 2019; 18: 563-568. 
31. Tóth, KF, Ádám D, Bíró T, Oláh A. Cannabinoid signaling in the skin: therapeutic potential of the “C(ut)annabinoid” system. Molecules 2019; 24: 918. 
32. Botanix Pharmaceuticals. Permetrex outperforms other CBD topical products. ASX media release; 26 February 2019. Available online at: https://www.asx.com.au/asxpdf/20190226/pdf/442z4fm2rq3kkh.pdf (accessed November 2020).